Nasdaq · CIK 0002096997
KLRA Kailera Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 34 d ago. Close $11.61 on Oct 9, 2026, +16% from the 52-week low and -55% from the high.
Kailera Therapeutics, Inc. (KLRA) has 19 SEC Form 4 filings on file from 18 insiders, the latest filed on Sep 9, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
5 open-market trades have been scored at KLRA. The newest: Rtw Investments, LP (10% owner) bought $8.0M of stock on Apr 20, 2026, filed Apr 22, 2026, scored 57 (moderate). The largest of the 5 shown: Bain Capital Investors LLC (10% owner) bought $134M on Apr 20, 2026, scored 63 (notable). 5 insiders bought within 14 days of each other around Apr 20, 2026.
KLRA closed at $11.61 on Oct 9, 2026, 16% above its 52-week low and 55% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Kailera Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Rtw Investments, LP owner buy | $8.0M 500,000 shares | +5% | 0% from low-5% from high | |
| 63Notable | Bain Capital Investors LLC owner buy | $134M 8,398,438 shares | +47% | 0% from low-5% from high | |
| 60Notable | Bain Capital Life Sciences Investors, LLC owner buy | $25M 1,562,500 shares | +7% | 0% from low-5% from high | |
| 71Notable | Andrew T. Kaplan director, owner buy | $134M 8,398,438 shares | +47% | 0% from low-5% from high | |
| 68Notable | Adam Koppel director, owner buy | $25M 1,562,500 shares | +7% | 0% from low-5% from high |
Transactions
Every row filed, 47 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 7, 2026 | Nur Nicholson Chief Technology Officer | AGrant or award Stock Option (right to buy)derivative | +220,000 | $0.00 | $0 | 220,000 | 34 d ago |
| Jun 9, 2026 | Ronald C Renaud JR CEO & President | MOption exercise Common Stock | +38,094 | $5.25 | $200k | 38,094 | Jun 11, 2026 |
| Jun 9, 2026 | Ronald C Renaud JR CEO & President | MOption exercise Stock Option (right to buy)derivative | -38,094 | $0.00 | $0 | 817,826 | Jun 11, 2026 |
| Apr 20, 2026 | Rtw Investments, LP owner | CConversion Common Stockindirect: See footnote | +10,276,820 | - | - | 10,276,820 | Apr 22, 2026 |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. owner | CConversion Common Stock | +9,477,719 | - | - | 9,477,719 | Apr 22, 2026 |
| Apr 20, 2026 | Rtw Investments, LP owner | POpen-market purchase Common Stockindirect: See footnote | +500,000 | $16.00 | $8.0M | 10,776,820 | Apr 22, 2026 |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. owner | CConversion Common Stock | +2,034,133 | - | - | 2,034,133 | Apr 22, 2026 |
| Apr 20, 2026 | Rtw Investments, LP owner | CConversion Series A Preferred Stockderivativeindirect: See footnote | -8,250,000 | - | - | 0 | Apr 22, 2026 |
| Apr 20, 2026 | Rtw Investments, LP owner | CConversion Series B Preferred Stockderivativeindirect: See footnote | -2,026,820 | - | - | 0 | Apr 22, 2026 |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. owner | CConversion Series A-2 convertible preferred stockderivative | -4,968,789 | $0.00 | $0 | 0 | Apr 22, 2026 |
| Apr 20, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. owner | CConversion Series A-2 convertible non-voting preferred stockderivative | -708,814 | $0.00 | $0 | 0 | Apr 22, 2026 |
| Apr 16, 2026 | Christopher Hite director | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
| Apr 16, 2026 | Douglas W. Pagan Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 20, 2026 |
| Apr 16, 2026 | Scott M. Wasserman Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 20, 2026 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC owner | CConversion Common Stockindirect: See footnotes | +16,875,000 | - | - | 16,875,000 | Apr 20, 2026 |
| Apr 16, 2026 | Jamie Beth Coleman Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Apr 20, 2026 |
| Apr 16, 2026 | Frank Clyburn director | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
| Apr 16, 2026 | Paula Cloghessy Chief People Officer | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Apr 20, 2026 |
| Apr 16, 2026 | Paul D. Burgess See Remarks | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 20, 2026 |
| Apr 16, 2026 | Scott Akamine Chief Legal Officer | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Apr 20, 2026 |
| Apr 16, 2026 | Martin Mackay director | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
| Apr 16, 2026 | John F Milligan director | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
| Apr 16, 2026 | Ronald C Renaud JR CEO & President | AGrant or award Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Apr 20, 2026 |
| Apr 20, 2026 | Bain Capital Investors LLC owner | CConversion Common Stockindirect: See footnotes | +17,857,143 | - | - | 17,857,143 | Apr 20, 2026 |
| Apr 20, 2026 | Andrew T. Kaplan director, owner | CConversion Common Stockindirect: See footnotes | +17,857,143 | - | - | 17,857,143 | Apr 20, 2026 |
| Apr 20, 2026 | Adam Koppel director, owner | CConversion Common Stockindirect: See footnotes | +16,875,000 | - | - | 16,875,000 | Apr 20, 2026 |
| Apr 16, 2026 | Jamie Beth Coleman Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Apr 20, 2026 |
| Apr 16, 2026 | Ronald C Renaud JR CEO & President | AGrant or award Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Apr 20, 2026 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC owner | CConversion Common Stockindirect: See footnotes | +4,145,768 | - | - | 21,020,768 | Apr 20, 2026 |
| Apr 16, 2026 | Scott M. Wasserman Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 20, 2026 |
| Apr 16, 2026 | Douglas W. Pagan Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 20, 2026 |
| Apr 20, 2026 | Bain Capital Investors LLC owner | POpen-market purchase Common Stockindirect: See footnotes | +8,398,438 | $16.00 | $134M | 26,255,581 | Apr 20, 2026 |
| Apr 20, 2026 | Andrew T. Kaplan director, owner | POpen-market purchase Common Stockindirect: See footnotes | +8,398,438 | $16.00 | $134M | 26,255,581 | Apr 20, 2026 |
| Apr 16, 2026 | Paula Cloghessy Chief People Officer | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Apr 20, 2026 |
| Apr 16, 2026 | Paul D. Burgess See Remarks | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 20, 2026 |
| Apr 16, 2026 | Scott Akamine Chief Legal Officer | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Apr 20, 2026 |
| Apr 20, 2026 | Adam Koppel director, owner | CConversion Common Stockindirect: See footnotes | +4,145,768 | - | - | 21,020,768 | Apr 20, 2026 |
| Apr 20, 2026 | Adam Koppel director, owner | POpen-market purchase Common Stockindirect: See footnotes | +1,562,500 | $16.00 | $25M | 22,583,268 | Apr 20, 2026 |
| Apr 20, 2026 | Andrew T. Kaplan director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -17,857,143 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC owner | POpen-market purchase Common Stockindirect: See footnotes | +1,562,500 | $16.00 | $25M | 22,583,268 | Apr 20, 2026 |
| Apr 20, 2026 | Bain Capital Investors LLC owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -17,857,143 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 16, 2026 | Andrew T. Kaplan director, owner | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC owner | CConversion Series A-1 Preferred Stockderivativeindirect: See footnotes | -16,875,000 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | Adam Koppel director, owner | CConversion Series A-1 Preferred Stockderivativeindirect: See footnotes | -16,875,000 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | Adam Koppel director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -4,145,768 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 20, 2026 | Bain Capital Life Sciences Investors, LLC owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -4,145,768 | $0.00 | $0 | 0 | Apr 20, 2026 |
| Apr 16, 2026 | Adam Koppel director, owner | AGrant or award Stock Option (right to buy)derivative | +38,300 | $0.00 | $0 | 38,300 | Apr 20, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Scott AkamineChief Legal Officer
- Bain Capital Investors LLCowner
- Bain Capital Life Sciences Investors, LLCowner
- Paul D. BurgessSee Remarks
- Paula CloghessyChief People Officer
- Frank Clyburndirector
- Jamie Beth ColemanChief Commercial Officer
- Christopher Hitechair, officer, director
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.owner
- Andrew T. Kaplandirector, owner
- Adam Koppeldirector, owner
- Martin Mackaydirector
- John F Milligandirector
- Nur NicholsonChief Technology Officer
- Douglas W. PaganChief Financial Officer
- Rtw Investments, LPdirector, owner, other
- Ronald C Renaud JRCEO & President
- Scott M. WassermanChief Medical Officer
Questions about KLRA
Answered from the filings on this page, as of the latest one.
Are insiders buying KLRA?
No. In the last 90 days no insider at Kailera Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade KLRA on the open market?
Rtw Investments, LP (10% owner) bought $8.0M of KLRA on Apr 20, 2026 and filed the Form 4 on Apr 22, 2026. InsiderTell scored 57 (moderate), with 5 insiders on the same side within 14 days.
How many insiders file Form 4 at Kailera Therapeutics, Inc.?
18 people have filed a Form 4 at Kailera Therapeutics, Inc., among them Scott Akamine (Chief Legal Officer), Bain Capital Investors LLC (10% owner), Bain Capital Life Sciences Investors, LLC (10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.